Patents by Inventor Kazuyasu Nakamura

Kazuyasu Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-PERP recombinant antibody
    Patent number: 8093362
    Abstract: An antibody which binds to a polypeptide encoded by human PERP (p53 apoptosis effector related to PMP-22) gene which is considered to be related to incidence of cancer or the like is desired. The present invention provides a gene recombinant antibody which has no consensus sequence of an N-linked sugar chain in a variable region, specifically recognizes three-dimensional structure of an extracellular region of a polypeptide encoded by the PERP gene and binds to the extracellular region. The antibody is useful for treatment of various diseases expressing a polypeptide encoded by the PERP gene.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: January 10, 2012
    Assignees: Kyowa Hakko Kirin Co., Ltd., Japan as Represented by President of National Cancer Center
    Inventors: Atsushi Ochiai, Emi Hosaka, Kazuyasu Nakamura, Akiko Furuya, Yuji Ohki
  • Anti-claudin-4 antibody
    Patent number: 8076458
    Abstract: An object of the present invention is to provide a monoclonal antibody which is useful as a diagnostic agent or a therapeutic agent for a disease relating to a polypeptide encoded by Claudin-4 (hereinafter referred to as “CLDN4”) gene or a polypeptide encoded by a Claudin-3 (hereinafter referred to as “CLDN3”) gene, or a method for using the same.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: December 13, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: So Ohta, Hiroshi Ando, Masayo Suzuki, Shinobu Kawamoto, Mariko Nakano, Kazuyasu Nakamura
  • Antibody composition-producing cell with inactivated A-1,6-fusocyltransferase
    Patent number: 8067232
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: November 29, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Glycoengineered, recombinant antibody to CCR-4 with reduced fucosylation
    Patent number: 8039595
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: October 18, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • ANTIBODY COMPOSITION-PRODUCING CELL
    Publication number: 20110250643
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Application
    Filed: May 6, 2011
    Publication date: October 13, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Yutaka KANDA, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Humanized antibody against fibroblast growth factor-8 and antibody fragment thereof
    Patent number: 7939077
    Abstract: The present invention relates to an antibody against FGF-8, particularly a humanized antibody against FGF-8 and the antibody fragment thereof, a DNA sequence encoding the above antibody or the antibody fragment, a vector comprising the DNA sequence and a host cell transformed by the vector, a production process of the above antibody or the antibody fragment using the host cell, and a therapeutic agent and a diagnostic agent for cancer using the antibody or the antibody fragment.
    Type: Grant
    Filed: June 28, 2002
    Date of Patent: May 10, 2011
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Maiko Hirota, Naoki Shimada
  • ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION
    Publication number: 20110059115
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Application
    Filed: June 18, 2010
    Publication date: March 10, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: YUTAKA KANDA, MITSUO SATOH, KAZUYASU NAKAMURA, KAZUHISA UCHIDA, TOYOHIDE SHINKAWA, NAOKO YAMANE, EMI HOSAKA, KAZUYA YAMANO, MOTOO YAMASAKI, NOBUO HANAI
  • HUMAN CDR-GRAFTED ANTIBODY AND ANTIBODY FRAGMENT THEREOF
    Publication number: 20110059524
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Application
    Filed: October 13, 2010
    Publication date: March 10, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenya SHITARA, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION
    Publication number: 20110052610
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Application
    Filed: June 18, 2010
    Publication date: March 3, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20110052595
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: June 30, 2009
    Publication date: March 3, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD
    Inventors: Eisuke MEKADA, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20110034673
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: October 30, 2009
    Publication date: February 10, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Eisuke MEKADA, Ryo IWAMOTO, Shingo MIYAMOTO, Kenya SHITARA, Akiko FURUYA, Kazuyasu NAKAMURA, Kumiko TAKAHASHI, Hiroshi ANDO, Kazuhiro MASUDA, Yuka SASAKI
  • ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION
    Publication number: 20110027271
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof.
    Type: Application
    Filed: June 16, 2010
    Publication date: February 3, 2011
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Yutaka KANDA, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
    Patent number: 7851601
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Grant
    Filed: December 8, 2008
    Date of Patent: December 14, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Eisuke Mekada, Ryo Iwamoto, Shingo Miyamoto, Kenya Shitara, Akiko Furuya, Kazuyasu Nakamura, Kumiko Takahashi, Hiroshi Ando, Kazuhiro Masuda, Yuka Sasaki
  • ANTI-CD4 ANTIBODY
    Publication number: 20100310573
    Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.
    Type: Application
    Filed: December 28, 2009
    Publication date: December 9, 2010
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Tomoaki NAKAGAWA, Sayaka HORI, Rinpei NIWA, Tsuguo KUBOTA, Kazuhiro MASUDA, Kazuyasu NAKAMURA
  • Antibody composition-producing cell in which enzyme expression is inhibited by RNAi
    Patent number: 7846725
    Abstract: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, wherein the expression of GDP-mannose 4,6-dehydrogenase is inhibited by RNA interference.
    Type: Grant
    Filed: April 1, 2008
    Date of Patent: December 7, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd
    Inventors: Yutaka Kanda, Mitsuo Satoh, Kazuyasu Nakamura, Kazuhisa Uchida, Toyohide Shinkawa, Naoko Yamane, Emi Hosaka, Kazuya Yamano, Motoo Yamasaki, Nobuo Hanai
  • Human CDR-grafted antibody and antibody fragment thereof
    Patent number: 7842797
    Abstract: A human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human CC chemokine receptor 4 (CCR4) but does not react with a human blood platelet; a human CDR-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of CCR4 and has a cytotoxic activity against a CCR4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.
    Type: Grant
    Filed: February 27, 2009
    Date of Patent: November 30, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kenya Shitara, Kazuyasu Nakamura, Emi Hosaka, Akiko Shimizu, Masamichi Koike
  • Method for Treating the TH2-Mediated Disease
    Publication number: 20100221178
    Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.
    Type: Application
    Filed: January 8, 2010
    Publication date: September 2, 2010
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Kenya SHITARA, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
  • METHOD OF MODULATING THE ACTIVITY OF FUNCTIONAL IMMUNE MOLECULES
    Publication number: 20100196371
    Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.
    Type: Application
    Filed: December 23, 2009
    Publication date: August 5, 2010
    Applicant: KYOWA HAKKO KIRIN, LTD.
    Inventors: NOBUO HANAI, KAZUYASU NAKAMURA, EMI HOSAKA, MOTOO YAMASAKI, KAZUHISA UCHIDA, TOYOHIDE SHINKAWA, SUSUMU IMABEPPU, YUTAKA KANDA, NAOKO YAMANE, HIDEHARU ANAZAWA
  • Method of modulating the activity of functional immune molecules to platelet-derived growth factor receptor
    Patent number: 7763246
    Abstract: The invention relates to a method for controlling the activity of an immunologically functional molecule, such as an antibody, a protein, a peptide or the like, an agent of promoting the activity of an immunologically functional molecule, and an immunologically functional molecule having the promoted activity.
    Type: Grant
    Filed: March 15, 2007
    Date of Patent: July 27, 2010
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Nobuo Hanai, Kazuyasu Nakamura, Emi Hosaka, Motoo Yamasaki, Kazuhisa Uchida, Toyohide Shinkawa, Susumu Imabeppu, Yutaka Kanda, Naoko Yamane, Hideharu Anazawa
  • MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR
    Publication number: 20100184958
    Abstract: Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF.
    Type: Application
    Filed: December 8, 2008
    Publication date: July 22, 2010
    Applicant: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: EISUKE MEKADA, RYO IWAMOTO, SHINGO MIYAMOTO, KENYA SHITARA, AKIKO FURUYA, KAZUYASU NAKAMURA, KUMIKO TAKAHASHI, HIROSHI ANDO, KAZUHIRO MASUDA, YUKA SASAKI